FXN and central nervous system cancer: We then tested these FXN-activating ASOs in more cell lines from various tissue origins including HEK-293T (kidney), JHH2 (hepatocellular carcinoma) and U87 (glioma) and observed significant FXN mRNA increase by S10+2, S10_L6 and S30 (Figure 4C).